EntryPoint Capital LLC Acquires Shares of 52,346 Cogent Biosciences, Inc. (NASDAQ:COGT)

EntryPoint Capital LLC bought a new position in Cogent Biosciences, Inc. (NASDAQ:COGT) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 52,346 shares of the technology company’s stock, valued at approximately $408,000.

Other large investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in Cogent Biosciences in the fourth quarter worth about $88,000. E Fund Management Co. Ltd. bought a new position in shares of Cogent Biosciences in the 4th quarter worth approximately $89,000. Proficio Capital Partners LLC purchased a new position in shares of Cogent Biosciences in the 4th quarter valued at approximately $93,000. Victory Capital Management Inc. purchased a new position in shares of Cogent Biosciences in the 3rd quarter valued at approximately $113,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Cogent Biosciences during the third quarter valued at approximately $134,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on COGT shares. Needham & Company LLC reiterated a “hold” rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Piper Sandler upgraded shares of Cogent Biosciences to a “strong-buy” rating in a research note on Friday, March 7th. Wedbush reissued a “neutral” rating and set a $11.00 price objective on shares of Cogent Biosciences in a research note on Tuesday, February 25th. HC Wainwright decreased their target price on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Finally, Scotiabank assumed coverage on shares of Cogent Biosciences in a report on Friday, March 7th. They set a “sector outperform” rating and a $17.00 target price for the company. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Cogent Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $14.43.

Cogent Biosciences Stock Down 6.8 %

NASDAQ:COGT opened at $6.90 on Wednesday. The stock has a market cap of $785.57 million, a price-to-earnings ratio of -2.78 and a beta of 1.80. The company’s 50 day moving average price is $7.96 and its 200-day moving average price is $9.18. Cogent Biosciences, Inc. has a 52 week low of $5.79 and a 52 week high of $12.61.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.